Journal of Korean Neurosurgical Society

The Korean Neurosurgical Society (대한신경외과학회)
권호 표지
DOI QR코드

DOI QR Code

Outcome of Endoscopic Transsphenoidal Surgery in Combination with Somatostatin Analogues in Patients with Growth Hormone Producing Pituitary Adenoma

  • Zhou, Tao (Department of Neurosurgery, General Hospital of People's Liberation Army) ;
  • Wang, Fuyu (Department of Neurosurgery, General Hospital of People's Liberation Army) ;
  • Meng, Xianghui (Department of Neurosurgery, General Hospital of People's Liberation Army) ;
  • Ba, Jianmin (Department of Endocrinology, General Hospital of People's Liberation Army) ;
  • Wei, Shaobo (Department of Neurosurgery, General Hospital of People's Liberation Army) ;
  • Xu, Bainan (Department of Neurosurgery, General Hospital of People's Liberation Army)
  • Received : 2014.01.16
  • Accepted : 2014.05.05
  • Published : 2014.11.28
Download PDF
⟨ Previous Next ⟩

Abstract

Objective : To determine the efficacy of endoscopic surgery in combination with long-acting somatostatin analogues (SSAs) in treating patients with growth hormone (GH)-secreting pituitary tumor. Methods : We performed retrospective analysis of 133 patients with GH producing pituitary adenoma who underwent pure endoscopic transsphenoidal surgery in our center from January 2007 to July 2012. Patients were followed up for a range of 3-48 months. The radiological remission, biochemical remission and complication were evaluated. Results : A total of 110 (82.7%) patients achieved radiological complete resection, 11 (8.2%) subtotal resection, and 12 (9.0%) partial resection. Eighty-eight (66.2%) patients showed nadir GH level less than 1 ng/mL after oral glucose administration. No mortality or severe disability was observed during follow up. Preoperative long-acting SSA successfully improved left ventricle ejection fraction (LVEF) and blood glucose in three patients who subsequently underwent success operation. Long-acting SSA (20 mg every 30 days) achieved biochemical remission in 19 out 23 (82.6%) patients who showed persistent high GH level after surgery. Conclusion : Endoscopic transsphenoidal surgery can biochemically cure the majority of GH producing pituitary adenoma. Post-operative use of SSA can improve biochemical remission.

Keywords

References

  1. Barker FG 2nd, Klibanski A, Swearingen B : Transsphenoidal surgery for pituitary tumors in the United States, 1996-2000 : mortality, morbidity, and the effects of hospital and surgeon volume. J Clin Endocrinol Metab 88 : 4709-4719, 2003 https://doi.org/10.1210/jc.2003-030461
  2. Colao A, Martino E, Cappabianca P, Cozzi R, Scanarini M, Ghigo E; A.L.I. C.E. Study Group : First-line therapy of acromegaly : a statement of the A. L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study Group. J Endocrinol Invest 29 : 1017-1020, 2006 https://doi.org/10.1007/BF03349217
  3. Gittoes NJ, Sheppard MC, Johnson AP, Stewart PM : Outcome of surgery for acromegaly--the experience of a dedicated pituitary surgeon. QJM 92 : 741-745, 1999 https://doi.org/10.1093/qjmed/92.12.741
  4. Hlavica M, Bellut D, Lemm D, Schmid C, Bernays RL : Impact of ultra-low-field intraoperative magnetic resonance imaging on extent of resection and frequency of tumor recurrence in 104 surgically treated nonfunctioning pituitary adenomas. World Neurosurg 79 : 99-109, 2013 https://doi.org/10.1016/j.wneu.2012.05.032
  5. Hofstetter CP, Mannaa RH, Mubita L, Anand VK, Kennedy JW, Dehdashti AR, et al. : Endoscopic endonasal transsphenoidal surgery for growth hormone-secreting pituitary adenomas. Neurosurg Focus 29 : E6, 2010
  6. Holdaway IM, Bolland MJ, Gamble GD : A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol 159 : 89-95, 2008 https://doi.org/10.1530/EJE-08-0267
  7. Jane JA Jr, Starke RM, Elzoghby MA, Reames DL, Payne SC, Thorner MO, et al. : Endoscopic transsphenoidal surgery for acromegaly : remission using modern criteria, complications, and predictors of outcome. J Clin Endocrinol Metab 96 : 2732-2740, 2011 https://doi.org/10.1210/jc.2011-0554
  8. Katznelson L, Atkinson JL, Cook DM, Ezzat SZ, Hamrahian AH, Miller KK; American Association of Clinical Endocrinologists : American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly--2011 update. Endocr Pract 17 Suppl 4 : 1-44, 2011
  9. Maison P, Tropeano AI, Macquin-Mavier I, Giustina A, Chanson P : Impact of somatostatin analogs on the heart in acromegaly : a metaanalysis. J Clin Endocrinol Metab 92 : 1743-1747, 2007 https://doi.org/10.1210/jc.2006-2547
  10. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, et al. : Guidelines for acromegaly management : an update. J Clin Endocrinol Metab 94 : 1509-1517, 2009 https://doi.org/10.1210/jc.2008-2421
  11. Nomikos P, Buchfelder M, Fahlbusch R : The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. Eur J Endocrinol 152 : 379-387, 2005 https://doi.org/10.1530/eje.1.01863
  12. Pita-Gutierrez F, Pertega-Diaz S, Pita-Fernandez S, Pena L, Lugo G, Sangiao-Alvarellos S, et al. : Place of preoperative treatment of acromegaly with somatostatin analog on surgical outcome : a systematic review and meta-analysis. PLoS One 8 : e61523, 2013 https://doi.org/10.1371/journal.pone.0061523
  13. Plockinger U, Quabbe HJ : Presurgical octreotide treatment in acromegaly : no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study. Acta Neurochir (Wien) 147 : 485-493; discussion 493, 2005 https://doi.org/10.1007/s00701-005-0511-9
  14. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK : Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 41 : 95-102, 1994 https://doi.org/10.1111/j.1365-2265.1994.tb03789.x
  15. Schwartz TH, Stieg PE, Anand VK : Endoscopic transsphenoidal pituitary surgery with intraoperative magnetic resonance imaging. Neurosurgery 58 (1 Suppl) : ONS44-ONS51; discussion ONS44-ONS51, 2006
  16. Shen M, Shou X, Wang Y, Zhang Z, Wu J, Mao Y, et al. : Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas : a prospective randomized study. Endocr J 57 : 1035-1044, 2010 https://doi.org/10.1507/endocrj.K10E-203
  17. Wu JS, Shou XF, Yao CJ, Wang YF, Zhuang DX, Mao Y, et al. : Transsphenoidal pituitary macroadenomas resection guided by PoleStar N20 low-field intraoperative magnetic resonance imaging : comparison with early postoperative high-field magnetic resonance imaging. Neurosurgery 65 : 63-70; discussion 70-71, 2009 https://doi.org/10.1227/01.NEU.0000348549.26832.51

Cited by

  1. Parasellar Extension Grades and Surgical Extent in Endoscopic Endonasal Transsphenoidal Surgery for Pituitary Adenomas : A Single Surgeon's Consecutive Series with the Aspects of Reliability and Clini vol.59, pp.6, 2016, https://doi.org/10.3340/jkns.2016.59.6.577
  2. Microsurgical versus endoscopic transsphenoidal resection for acromegaly: a systematic review of outcomes and complications vol.159, pp.11, 2014, https://doi.org/10.1007/s00701-017-3318-6
  3. Gross total resection of pituitary adenomas after endoscopic vs. microscopic transsphenoidal surgery: a meta-analysis vol.160, pp.5, 2014, https://doi.org/10.1007/s00701-017-3438-z